Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.
Elif I Ekinci, Sandra González Maldonado, Anna Unseld et al.
✦ AI-curated · Sources linked
In 30 seconds
This post hoc analysis of two phase 2 randomized controlled trials evaluated the effects of survodutide on beta-cell function and insulin sensitivity in 800 participants with type 2 diabetes or overweight/obesity. Survodutide significantly improved HOMA-β and reduced HOMA-IR, glucagon, and fasting plasma glucose in the diabetes cohort, while also enhancing insulin sensitivity in the overweight/obesity group, independent of bodyweight changes.
Key findings
- In trial 1404-0002, survodutide increased HOMA-β and decreased HOMA-IR compared to placebo.
- In trial 1404-0036, survodutide led to significant decreases in fasting insulin and fasting plasma glucose.
- Survodutide improved insulin sensitivity independent of bodyweight changes.
- No significant changes were observed in C-peptide or fasting insulin levels in the diabetes cohort.
Why it matters
The findings suggest that survodutide may offer metabolic benefits for individuals with type 2 diabetes and those with overweight or obesity, potentially enhancing treatment options beyond traditional weight loss strategies.